ADVISORY, Jan. 25, 2007 (PRIME NEWSWIRE) --
What: Hojabr Alimi, Chief Executive Officer of Oculus Innovative Sciences, Inc. (OCLS) will preside over the closing bell to celebrate the Company's initial public offering on NASDAQ. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Friday, January 26, 2007 at 4 p.m. ET Contacts: Oculus Innovative Sciences, Inc. Dan McFadden; 425.753.2105 email@example.com or Jason Rando; 646.536.7025 firstname.lastname@example.org NASDAQ MarketSite: Jolene Libretto; 646.441.5220; 347.219.9539 Jolene.Libretto@NASDAQ.com
The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at (646) 441-5220.
A live Webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Oculus Innovative Sciences, Inc. (OCLS):
Oculus Innovative Sciences, Inc. is a medical technology company focused on the development, manufacture and marketing of a family of products intended to help prevent and treat infection in acute and chronic wounds. Oculus' platform technology, called Microcyn(r), is a non-irritating, super-oxidized, water-based solution that is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, as well as viruses, fungi and spores.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.
In This StoryNDAQ
Nasdaq Press Center
Read the latest press releases, request a press kit, and get in touch with our press team.